Ocular Therapeutix, Inc.
OCUL Healthcare Biotechnology
Ocular Therapeutix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $52.0 million, down 18.5% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 10.3%, free cash flow fell 25.4% and total debt rose 4.13%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow OCUL
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
+8 more quarters Free account |
344.77 | 737.06 | 666.70 | 598.64 |
Receivables |
30.77 | 30.65 | 24.35 | 30.26 | |
Inventory |
3.49 | 3.56 | 3.74 | 3.83 | |
Total current assets |
386.98 | 782.13 | 706.00 | 644.43 | |
Property, Plant, Equpment (Net) |
16.95 | 19.68 | 18.43 | 19.46 | |
Long-term assets (Other) |
1.61 | 1.61 | 1.61 | 1.61 | |
Total non-current assets |
23.90 | 25.93 | 26.53 | 26.89 | |
Total Assets |
410.88 | 808.06 | 732.53 | 671.32 | |
Accounts Payable |
6.26 | 4.15 | 8.03 | 7.00 | |
Accrued Expenses |
40.27 | 43.84 | 36.49 | 39.06 | |
Current Revenue (Deferred) |
0.00 | — | — | — | |
Total current liabilities |
49.29 | 50.81 | 47.68 | 49.17 | |
Long Term Debt (Total) |
70.62 | 71.34 | 72.06 | 72.80 | |
Non-current Revenue (Deferred) |
14.00 | 14.00 | 14.00 | 14.00 | |
Non-current Liabilities (Other) |
15.11 | 14.79 | 12.98 | 11.84 | |
Total non-current liabilities |
103.36 | 102.94 | 103.27 | 102.10 | |
Total liabilities |
152.65 | 153.75 | 150.96 | 151.28 | |
Additional Paid In Capital |
1,350.58 | 1,811.31 | 1,827.19 | 1,844.42 | |
Common Stock (Net) |
0.02 | 0.02 | 0.02 | 0.02 | |
Retained Earnings |
(1,092.37) | (1,157.02) | (1,245.63) | (1,324.40) | |
Common Equity (Total) |
258.23 | 654.31 | 581.57 | 520.04 | |
Shareholders Equity (Total) |
258.23 | 654.31 | 581.57 | 520.04 | |
Shareholders Equity and Liabilities (Total) |
410.88 | 808.06 | 732.53 | 671.32 | |
Shares (Common) |
174.95 | 215.93 | 218.90 | 219.59 | |
Shareholders Equity (Tangible) |
258.23 | 654.31 | 581.57 | 520.04 | |
Net Debt |
(274.15) | (665.72) | (594.64) | (525.85) | |
Total Debt |
70.62 | 71.34 | 72.06 | 72.80 |